SG10201505503WA - Dry-coated tablet containing tegafur, gimeracil and oteracil potassium - Google Patents

Dry-coated tablet containing tegafur, gimeracil and oteracil potassium

Info

Publication number
SG10201505503WA
SG10201505503WA SG10201505503WA SG10201505503WA SG10201505503WA SG 10201505503W A SG10201505503W A SG 10201505503WA SG 10201505503W A SG10201505503W A SG 10201505503WA SG 10201505503W A SG10201505503W A SG 10201505503WA SG 10201505503W A SG10201505503W A SG 10201505503WA
Authority
SG
Singapore
Prior art keywords
gimeracil
dry
coated tablet
tablet containing
oteracil potassium
Prior art date
Application number
SG10201505503WA
Other languages
English (en)
Inventor
Takumi Okamoto
Takashi Yoshizawa
Yoshito Ohnishi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG10201505503WA publication Critical patent/SG10201505503WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201505503WA 2011-05-25 2012-05-24 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium SG10201505503WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011116884 2011-05-25

Publications (1)

Publication Number Publication Date
SG10201505503WA true SG10201505503WA (en) 2015-09-29

Family

ID=47217314

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013083829A SG194922A1 (en) 2011-05-25 2012-05-24 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
SG10201505503WA SG10201505503WA (en) 2011-05-25 2012-05-24 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013083829A SG194922A1 (en) 2011-05-25 2012-05-24 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium

Country Status (15)

Country Link
US (1) US20140335174A1 (ko)
EP (1) EP2716290B1 (ko)
JP (2) JP5689173B2 (ko)
KR (2) KR20170072959A (ko)
AU (1) AU2012259803B2 (ko)
BR (1) BR112013030093B1 (ko)
CA (1) CA2836865C (ko)
ES (1) ES2671926T3 (ko)
IL (1) IL229372B (ko)
MX (1) MX353289B (ko)
MY (1) MY167883A (ko)
RU (1) RU2601620C2 (ko)
SG (2) SG194922A1 (ko)
TW (2) TWI566787B (ko)
WO (1) WO2012161240A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI566787B (zh) * 2011-05-25 2017-01-21 Taiho Pharmaceutical Co Ltd Contains tegafur, gemcopyrimidine, otiorasilide potassium tablets (b)
CN107837273A (zh) * 2016-09-18 2018-03-27 江苏金甙生物技术有限公司 一种肠溶替吉奥缓释制剂及其制备方法
CN107865871B (zh) * 2016-09-23 2021-09-03 江苏恒瑞医药股份有限公司 一种替吉奥组合物及其制备方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
WO2023238929A1 (ja) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 ピミテスピブを含有する医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2614164B2 (ja) * 1991-05-27 1997-05-28 大鵬薬品工業株式会社 抗腫瘍効果増強のための及び腫瘍治療のための組成物
AU741992B2 (en) * 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
US7276252B2 (en) * 2000-05-18 2007-10-02 Massachusetts Institute Of Technology Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
DE20220415U1 (de) * 2001-11-07 2003-10-09 Synthon Bv Tamsulosin-Tabletten
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
JP2005526095A (ja) * 2002-03-20 2005-09-02 エラン ファーマ インターナショナル，リミティド 脆砕性の低い急速溶解投与剤型
CN101357134A (zh) * 2003-03-14 2009-02-04 大鹏药品工业株式会社 抗肿瘤效果增强剂和抗肿瘤剂
WO2005030177A2 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
CN100333726C (zh) 2004-12-23 2007-08-29 鲁南制药集团股份有限公司 含有替加氟、吉莫斯特和氧嗪酸钾的口腔崩解片
JP4956423B2 (ja) * 2005-04-01 2012-06-20 大鵬薬品工業株式会社 放射線治療増強剤
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
WO2009084216A1 (ja) * 2007-12-27 2009-07-09 Taiho Pharmaceutical Co., Ltd. 経口粉粒状抗腫瘍剤
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
KR100934876B1 (ko) 2008-01-31 2010-01-06 성균관대학교산학협력단 Ｌｉｇａ공정의 도금방법
CN101380327B (zh) * 2008-10-09 2011-01-26 北京恒瑞康达医药科技发展有限公司 抗癌复合缓释组合物及制备
JP5553522B2 (ja) 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
AU2010248710A1 (en) * 2009-05-12 2011-12-01 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
CN101711765B (zh) * 2009-10-31 2011-03-23 山东新时代药业有限公司 一种含有替加氟、吉美嘧啶和奥替拉西钾的分散片
TWI566787B (zh) * 2011-05-25 2017-01-21 Taiho Pharmaceutical Co Ltd Contains tegafur, gemcopyrimidine, otiorasilide potassium tablets (b)
CN102614183B (zh) * 2012-03-05 2013-10-30 齐鲁制药(海南)有限公司 一种替吉奥的口服制剂

Also Published As

Publication number Publication date
KR20140037879A (ko) 2014-03-27
BR112013030093B1 (pt) 2019-12-10
JP2014218523A (ja) 2014-11-20
EP2716290A4 (en) 2014-11-26
CA2836865A1 (en) 2012-11-29
KR101869127B1 (ko) 2018-06-19
SG194922A1 (en) 2013-12-30
KR20170072959A (ko) 2017-06-27
ES2671926T3 (es) 2018-06-11
JP5689173B2 (ja) 2015-03-25
TW201529100A (zh) 2015-08-01
TWI566787B (zh) 2017-01-21
NZ617625A (en) 2015-10-30
CA2836865C (en) 2018-02-27
IL229372B (en) 2018-12-31
JP5769853B2 (ja) 2015-08-26
MX353289B (es) 2018-01-05
BR112013030093A2 (pt) 2016-09-20
WO2012161240A1 (ja) 2012-11-29
TW201300141A (zh) 2013-01-01
EP2716290A1 (en) 2014-04-09
RU2601620C2 (ru) 2016-11-10
JPWO2012161240A1 (ja) 2014-07-31
AU2012259803B2 (en) 2016-03-17
TWI488659B (zh) 2015-06-21
MY167883A (en) 2018-09-26
MX2013013563A (es) 2013-12-16
US20140335174A1 (en) 2014-11-13
RU2013157528A (ru) 2015-06-27
IL229372A0 (en) 2014-01-30
EP2716290B1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
IL242286A0 (en) Modified 2)-n-methoxy-5-nitrophenyl)pyrimidine-2-amine compounds and their salts
ZA201308930B (en) Nitrogen containing compounds and their use
ZA201403503B (en) Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors
IL231009A0 (en) Bicyclic heteroaromatic compounds, their preparation and pharmaceutical preparations containing them
EP2725903A4 (en) 3-ALKOXY, THIOALKYL AND AMINO-4-AMINO-6- (SUBSTITUTED) PICOLINATES AND THEIR USE AS HERBICIDES
EP2789245A4 (en) EMULSION COMPOSITION AND COMPOSITION / INGREDIENTS
EP2661451A4 (en) ANTIMICROBIAL FUSION COMPOUNDS AND USES THEREOF
IL229372B (en) A dry-coated tablet containing tagfor, gimaracil and utracil potassium
ZA201307476B (en) New pyridazinone and pyridone compounds
EP2751758A4 (en) IMPROVING AN ONLINE BUY USER EXPERIENCE USING SOCIAL GRAPH INFORMATION
AP2012006232A0 (en) New association between 4-ä3-ÄCIS-hexahydrocyclopentaÄcÜpyrrol-2(1H)-YLÜpropoxyübenzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it.
AU2012259803A1 (en) Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
EP2857006A4 (en) DRY-COATED TABLET
EP2711704A4 (en) METHOD FOR SELECTION OF CHEMOTHERAPY FOR MAGICTRIC PATIENTS WITH A COMBINATION PREPARATION OF TEGAFUR, GIMERACIL AND OTERACIL KALIUM AND EGFR HEMMERN
HK1161971A1 (en) A capsule preparation containing tegafur, gimeracil and oteracil potassium
HK1211481A1 (en) Dry pressed coating tablet containing tegafur, gimeracil and oteracil potassium
HK1191942A1 (zh) 新型六氫環戊二烯並吡咯酮，六氫吡咯並吡咯酮，八氫吡咯並吡啶酮和八氫吡啶酮化合物
IL229206A0 (en) Preparation and tablet containing raltagravir
GB201110846D0 (en) Exchanging content and tools between users
HRP20160687T1 (hr) Supstituirani 2-(kroman-6-iloksi)tiazoli i njihova upotreba kao farmaceutska sredstva
IL232809A0 (en) Carboxamides converted at position 2 in isothiazolopyridine and their use as medicinal preparations
IL231096A (en) Theses are converted into 2- (novel-6-Iloxy) and used as pharmaceutical preparations
GB201111104D0 (en) Nanodern future technology- human mental alterness, focus and concentration enhancing spray formulation